Brinzolamide. Antiglaucoma, carbonic anhydrase inhibitor

Drugs of the Future

Volumn 23, Issue 4, 1998, Pages 365-369

  Wroblewski, T ^a   Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (ETHYLAMINO) 2 (3 METHOXYPROPYL) 3,4 DIHYDRO 2H THIENO[3,2 E] 1,2 THIAZINE 6 SULFONAMIDE 1,1 DIOXIDE; ANTIGLAUCOMA AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; UNCLASSIFIED DRUG;

AQUEOUS HUMOR OUTFLOW; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; REVIEW;

EID: 0031838597     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.04.453775     Document Type: Review

References (8)

1. Dean, T.R., Chen, H.-H., May, J.A. (Alcon Labs., Inc.). Sulfonamides useful as carbonic anhydrase inhibitors. US 5378703.
2. Dean, T.R., Chen, H.-H., May, J.A. (Alcon Labs., Inc.). Thiophene sulfonamides useful as carbonic anhydrase inhibitors. EP 527801, JP 93508832, US 5153192, US 5240923, WO 9115486.
3. Dean, W.D., Zinke, P.W., Sproull, S.J., Deason, M.E., Conrow, R.E., Dantanarayana, A.P. (Alcon Labs., Inc.). Preparation of carbonic anhydrase inhibitors. CA 2114877.
4. Dean, T., May, J., Chen, H.H., Kyba, E., McLaughlin, M., DeSantis, L. Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynomolgus monkey. Invest Ophthalmol Visual Sci 1997, 38(4, Part 2): Abst 3786.
5. Shin, D.H., The Brinzolamide Adjunctive Therapy Study Group. A triple-masked, placebo-controlled, adjunctive therapy study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5%. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 2605.
6. Stewart, R., The Brinzolamide Comfort Study Group. The ocular comfort of TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 2603.
7. Camras, C.B., The Brinzolamide Primary Therapy Study Group. A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1% compared to TID-dosed dorzolamide 2% and BID-dosed timolol 0.5%. Invest Ophthalmol Visual Sci 1997, 38(4, Part 1): Abst 2606.
8. First market introduction for Alcon's newest ophthalmic drug. Prous Science Daily Essentials May 5, 1998.